Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection

Journal of Infectious Diseases

Volumn 174, Issue 2, 1996, Pages 256-261

  Weltzin, R ^a   Traina Dorge, V ^b   Soike, K ^b   Zhang, J Y ^b   Mack, P ^b   Soman, G ^b   Drabik, G ^b   Monath, T P ^b  

^a Acambis   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HNK 20; NEUTRALIZING ANTIBODY; NOSE DROPS; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; HUMAN CELL; INTRANASAL DRUG ADMINISTRATION; LUNG LAVAGE; NONHUMAN; NOSE SECRETION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RHESUS MONKEY; THROAT CULTURE; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS SHEDDING;

EID: 0029898722     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.2.256     Document Type: Article

References (21)

1. Heilman CA. Respiratory syncytial and parainfiuenza viruses. J Infect Dis 1990;161:402-6.
2. McIntosh K, Chanock RM. Respiratory syncytial virus. In: Fields DN, Knipe DM, Chanock RM, et al., eds. Fields virology. 2nd ed. Vol 1. New York: Raven Press, 1990:1045-74.
3. Hemming VG, Prince GA, Groothuis JR, Siber GR. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev 1995;8:22-33.
4. Taylor G, Stott EJ, Bew M, et al. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 1984;52:137-42.
5. Walsh EE, Schlesinger JJ, Brandriss MW. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun 1984;43:756-8.
6. Prince GA, Hemming VG, Horswood RL, Chanock RM. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res 1985;3:193-206.
7. Crowe JE, Murphy BR, Chanock RM, Williamson RA, Barbas CF, Burton DR. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci USA 1994;91:1386-90.
8. Hemming VG, Prince GA, London WT, Baron PA, Brown R, Chanock RM. Topically administered immunoglobulin reduces pulmonary respiratory syncytial virus shedding in owl monkeys. Antimicrob Agents Chemother 1988;32:1269-70.
9. Piazza FM, Johnson SA, Ottolini MG, et al. Immunotherapy of respiratory syncytial virus infection in cotton rats (Sigmodon fulviventer) using IgG in a small-particle aerosol. J Infect Dis 1992;166:1422-4.
10. Prince GA, Hemming VG, Horswood RL, Baron PA, Chanock RM. Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J Virol 1987;61:1851-4.
11. Tempest PR, Bremner P, Lambert M, et al. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology 1991;9:266-71.
12. Weltzin R, Hsu SA, Mittler ES, Georgakopoulos K, Monath TP. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob Agents Chemother 1994;38:2785-91.
13. Beeler JA, van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 1989;63:2941-50.
14. Meissner HC. Economic impact of viral respiratory disease in children. J Pediatr 1994;124:S17-21.
15. Lee CK, Weltzin R, Soman G, Georgakopoulos KM, Houle DM, Monath TP. Oral administration of polymeric immunoglobulin A prevents colonization with Vibrio cholerae in neonatal mice. Infect Immun 1994;62:887-91.
16. Hall CB, Douglas RG. Modes of transmission of respiratory syncytial virus. J Pediatr 1981;99:100-3.
17. Graham BS, Tang YW, Gruber WC. Topical immunoprophylaxis of respiratory syncytial virus (RSV)-challenged mice with RSV-specific immune globulin. J Infect Dis 1995;171:1468-74.
18. Kakuk TJ, Soike K, Brideau RJ, et al. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a rccombinant FG subunit vaccine. J Infect Dis 1993;167:553-61.
19. Meissner HC, Fulton DR, Groothuis JR, et al. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob Agents Chemother 1993;37:1655-8.
20. Groothuis JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993;329:1524-30.
21. Schipper NG, Verhoef JC, Merkus FW. The nasal mucociliary clearance: relevance to nasal drug delivery. Pharm Res 1991;8:807-14.